| 前收盘价格 | 3.88 |
| 收盘价格 | 3.79 |
| 成交量 | 21,039 |
| 平均成交量 (3个月) | 106,544 |
| 市值 | 55,150,248 |
| 价格/销量 (P/S) | 220.99 |
| 52周波幅 | |
| 利润日期 | 13 Aug 2025 |
| 营业利益率 (TTM) | -5,032.10% |
| 稀释每股收益 (EPS TTM) | -4.03 |
| 季度收入增长率 (YOY) | 11.00% |
| 总债务/股东权益 (D/E MRQ) | 760.79% |
| 流动比率 (MRQ) | 1.36 |
| 营业现金流 (OCF TTM) | -19.25 M |
| 杠杆自由现金流 (LFCF TTM) | -8.61 M |
| 资产报酬率 (ROA TTM) | -49.62% |
| 股东权益报酬率 (ROE TTM) | -1,738.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Packaged Foods (US) | 混合的 | 看跌 |
| Packaged Foods (全球的) | 混合的 | 混合的 | |
| 股票 | Clene Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.9 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 相对估值 | NA |
| 财务健康 | -4.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -1.07 |
|
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46. |
|
| 部门 | Consumer Defensive |
| 行业 | Packaged Foods |
| 投资方式 | Small Value |
| 内部持股比例 | 34.60% |
| 机构持股比例 | 16.99% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lunt Capital Management, Inc. | 30 Jun 2026 | 52,260 |
| Parsons Capital Management Inc/Ri | 30 Jun 2026 | 37,243 |
该时间范围内无数据。
该时间范围内无数据。
投资组合